Company Intelligence
Pfizer is one of the world's largest biopharmaceutical companies, discovering, developing, manufacturing, and marketing medicines, vaccines, and consumer healthcare products. The company gained global recognition for its COVID-19 vaccine partnership with BioNTech and has since pivoted its strategy toward building a diversified, durable growth portfolio through major acquisitions (notably Seagen for $43 billion) and internal pipeline development across oncology, immunology, rare disease, and infectious disease.
Pharmaceuticals & Life Sciences
Headquarters
New York, NY
Employees
~83,000
Revenue
$58.5B (FY2024)
Fiscal Year End
December 31
Founded
1849
Current leadership team based on public filings and announcements.
Albert Bourla
CEO
David Denton
CFO
Key events and changes that sales teams should know about.
Executed a post-COVID portfolio pivot, investing billions to diversify beyond pandemic-era products. The strategy centers on oncology (via Seagen), weight management, and next-generation vaccines as the new growth engines.
2025-01
Integrated the $43 billion Seagen acquisition, gaining a leading antibody-drug conjugate (ADC) platform with marketed products Adcetris and Padcev, plus a deep oncology pipeline that transforms Pfizer into a top-tier oncology company.
2024-10
Launched a multi-billion-dollar cost restructuring program targeting $4B+ in annual savings by 2025, realigning the workforce and operations to the post-pandemic revenue baseline after COVID product sales declined sharply.
2024-08
Q3 2024 revenue of $17.7B showed stabilization as non-COVID product growth offset continued pandemic product declines, with oncology revenue growing 31% YoY following the Seagen acquisition.
2024-10
Expanded AI drug discovery capabilities through partnerships with technology companies and internal investment in machine learning platforms for target identification, molecule design, and clinical trial optimization.
2024-05
Pfizer is navigating one of the most dramatic revenue transitions in pharmaceutical history -- from a pandemic-driven peak of over $100 billion to a post-COVID baseline roughly half that size. The $43 billion Seagen acquisition is the centerpiece of its strategy to rebuild growth, making Pfizer one of the largest oncology companies in the world almost overnight. Vendors selling into pharma should understand that Pfizer is simultaneously integrating a massive acquisition, restructuring costs, and investing in new growth areas -- creating both budget pressure and significant procurement opportunities.
The Seagen integration creates a unique window for technology and services vendors. Pfizer needs to merge Seagen's research, commercial, and IT infrastructure with its own, which typically drives demand for integration platforms, data management tools, change management consulting, and commercial analytics. ADC manufacturing also requires specialized capabilities, potentially opening opportunities for contract manufacturing and supply chain technology vendors.
Pfizer's December 31 fiscal year end aligns with the standard calendar year. The company's major procurement cycles are influenced by both the calendar year budget process and the clinical trial lifecycle. R&D spending decisions often follow pipeline milestone events (clinical data readouts, regulatory submissions), while commercial operations spending follows product launch timelines. The ongoing cost restructuring also means procurement teams are under heightened scrutiny for ROI justification on new technology investments.
Key competitors based on market analysis and public filings.
Pfizer's fiscal year ends on December 31, following the standard calendar year. The company typically reports full-year results in late January or early February, with quarterly earnings in April, July, and October.
Pfizer generates approximately $58.5 billion in annual revenue as of FY2024. This represents a significant decline from the pandemic peak of over $100 billion in 2022, but reflects stabilization as non-COVID product growth -- particularly in oncology following the Seagen acquisition -- begins to offset pandemic product declines.
Pfizer is headquartered in New York City, at its corporate offices at 66 Hudson Boulevard East in the Hudson Yards development. The company was founded in Brooklyn, New York in 1849 by Charles Pfizer and Charles Erhart.
Pfizer acquired Seagen for $43 billion in 2023 to transform its oncology portfolio. Seagen is a pioneer in antibody-drug conjugates (ADCs), a rapidly growing class of cancer treatments that deliver targeted chemotherapy directly to tumor cells. The acquisition gave Pfizer marketed oncology products (Adcetris, Padcev), a deep pipeline, and a leading ADC technology platform -- helping offset the decline in COVID-19 product revenue.
Pfizer employs approximately 83,000 people globally, including the Seagen workforce integrated in 2024. The company has been undergoing a significant restructuring program to optimize costs, so headcount has been declining from a pandemic-era peak of over 90,000.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Pfizer — updated continuously.
